Nitric Oxide Synthase Market Size, Share, Growth, Trends, and Global Industry Analysis: Competitive Landscape, Pipeline, and Market Size, Share, Growth, Trends, and Global Industry Analysis: Analysis 2023

Nitric oxide synthases (NOSs) are a family of enzymes catalysing the production of nitric oxide (NO) from L-arginine. NO is an important cellular signaling molecule. It helps modulate vascular tone, insulin secretion, airway tone, and peristalsis and is involved in angiogenesis and neural development. It may function as a retrograde neurotransmitter. The mechanism of action (MOA) of Nitric Oxide Synthase is by tightly regulates nitric oxide (NO) synthesis and thereby its dual biological activities as a key signaling molecule for vasodilatation and neurotransmission at low concentrations, and also as a defensive cytotoxin at higher concentrations. Nitric Oxide Synthase analogs are used to treat CNS disorders, diabetes mellitus, gastrointestinal diseases, arthritis, migraine, joint diseases, endocrine gland disorder, skin diseases, and acne vulgaris among others. Increased prevalence of neurological disorders and autoimmune disorders are the key drivers for the Nitric Oxide Synthase market. For instance, According to the Centers for Disease Control and Prevention 2019, 37.3 million people of all ages or 11.3% of the US population had diabetes and the percentage of adults with diabetes increased with age, reaching 29.2% among those aged 65 years or older. Launch of newer products by the market players could seek opportunities that influence extensive research and development in Nitric Oxide Synthase Market. For instance, MediciNova’s Eyevinal (Ibudilast) is used to treat CNS disorders and viral infections. Moreover, the development of novel molecules by key players are coming up to overcome challenges in therapy. For instance, GSK’s GW-274150  for the treatment of autoimmune disorders and brain diseases are under the various stages of clinical studies.

Nitric Oxide Synthase Market Key Developments:

• In May 2021, Ono Pharma published that Arundic acid is an astrocyte-modulating agent, which delays the expansion of cerebral infarcts by modulating the activation of astrocytes through inhibition of S-100β synthesis and has the potential for stroke and Alzheimer’s disease research.

Approved Drug Molecules and Brand Names for Nitric Oxide Synthase:

• Eyevinal (Ibudilast)
• Cereact (Arundic Acid)

Drugs under the Pipeline for Nitric Oxide Synthase:

• Bardoxolone Methyl (RTA 402)
• Doxycycline Delayed-Release
• Gw-274150
• Shinbaro (GCSB-5)
• Diacerein Controlled Release (AC 201)
• Nxn-188
• Ronopterin (VAS203)
• Cindunistat (SC84250)
• Cr 3294
• Kd-7040

Clinical Activity and Developments of Nitric Oxide Synthase:

• Till June 2023, more than 12 companies have approximately 22 molecules targeting 470 diseases. For these molecules, more than 130 clinical trials are being conducted and the majority are in phase-2 and phase-3 clinical trials by the players across the globe. For instance,
• In December 2020, Reata Pharmaceuticals completed a phase 3 study of Bardoxolone Methyl for evaluating the efficacy and safety in patients with a connective tissue disease associated with pulmonary arterial hypertension.
• In April  2022, Ono Pharma completed phase 2, open-label, extension study for evaluating the safety and effect of Arundic Acid (ONO2506PO) in the patients with amyotrophic lateral sclerosis.